

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**Form 6-K**

---

**Report of Foreign Private Issuer  
Pursuant to Rule 13a-16 or 15d-16  
under the Securities Exchange Act of 1934**

**For the month of June, 2022**

**Commission File Number: 001-41106**

---

**Incannex Healthcare Limited**

(Exact name of Registrant as specified in its charter)

---

**not applicable**

(Translation of Registrant's name into English)

**Australia**

(Jurisdiction of incorporation or organization)

**Joel Latham**

**Chief Executive Officer and Managing Director**

**Level 39, Rialto South Tower**

**525 Collins Street**

**Melbourne 3000**

**Australia**

(Address of principal executive offices)

---

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F:

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes  No

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes  No

---

---

**INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K**

On June 28, 2022, Incannex Healthcare Limited filed with the Australian Securities Exchange an announcement captioned “Director and management update”, a copy of which announcement is attached to this Form 6-K as Exhibit 99.1.

On June 27, 2022, Incannex Healthcare Limited filed with the Australian Securities Exchange an announcement captioned “Incannex to Present at the H.C. Wainwright Conference”, a copy of which announcement is attached to this Form 6-K as Exhibit 99.2.

## Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

### **Incannex Healthcare Limited**

Date: June 28, 2022

By: /s/ Joel Latham

Name: Joel Latham

Title: Chief Executive Officer and Managing Director

## INDEX TO EXHIBITS

Exhibit No.

99.1	<a href="#">ASX Announcement, dated June 28, 2022 – Director and management update</a>
99.2	<a href="#">ASX Announcement, dated June 27, 2022 – Incannex to Present at the H.C. Wainwright Conference</a>



Date: June 28, 2022  
Public Announcement (NASDAQ: IXHL) (ASX: IHL)

**Director and management adjustments post acquisition of APIRx Pharmaceuticals; resignation of Dr Sud Agarwal and appointments of Dr George Anastassov and Mr Lekhram Changoer, MSc**

**Melbourne, Australia, June 28, 2022 – Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL)**, ('Incannex' or the 'Company') a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, wishes to advise that Dr Sud Agarwal has resigned as non-executive director.

Dr Agarwal's key contribution to the Company was his strategic vision and foresight to originate Incannex's proprietary cannabinoid combination drugs, IHL-42X, IHL-216A and IHL-675A (**Combination Compounds**). All pre-clinical and clinical studies undertaken to assess the Combination Compounds have been positive and the Company's understanding of their medical and commercial potential has advanced significantly during Dr Agarwal's tenure.

The clinical development activities associated with the Combination Compounds have been, and will continue to be managed by Chief Scientific Officer, Dr Mark Bleackley, who has been the Company's lead contact with the U.S. Food and Drug Administration ('FDA') and all relevant regulatory bodies, with input from the medical and scientific advisory team and contracted clinical research organisations. All psychedelic research and development activities are managed and led by Dr Paul Likhaitzky and his team at Monash University, there will be no disruptions to the current operational structure of the development of the Company's assets.

**Appointments of Dr George Anastassov and Mr Lekhram Changoer**

With effect from the closing of Incannex's acquisition of 100% of APIRx Pharmaceuticals, Dr George Anastassov, founding managing director of APIRx Pharmaceuticals, will replace Dr Agarwal on the board of directors. Co-founder of APIRx, Mr Lekhram Changoer (MSc) will join the Incannex management team as chief technology officer (CTO), responsible for the development and implementation of science and technical strategies for clinical and GMP-grade commercial manufacturing of pharmacotherapies.

Dr Anastassov and Mr Changoer will be employed by Incannex on a full-time basis. They will continue to drive the development of APIRx projects, whilst also being key members of the medical and scientific advisory team, assisting with the development of the Combination Compounds. Importantly for the progression of the Combination Compounds, Dr Anastassov and Mr Changoer are experienced with liaising and negotiating with FDA and the European Medicines Agency (EMA), having presented numerous regulatory submissions, including pre- investigational new drug ('IND') meeting packages and IND applications, to regulatory agencies over many years.

Furthermore, APIRx has strong relationships with international academic institutions and research hospitals including Mount Sinai School of Medicine, New York (USA), University of St. Andrews (UK), Free University of Amsterdam (NL), University of Wageningen (NL), and Mauritsclinics (NL). These relationships, among others, will be important to Incannex as all clinical research programs escalate.

Incannex Healthcare Limited (ABN: 93 096 635 246)  
Level 23, Rialto South Tower, 525 Collins Street, Melbourne VIC 3000  
P: +61 409 840 786

### **Strategic rationale for collegial management adjustments**

Following research success in the Combination Compounds and the acquisition of APIRx pharmaceuticals, which has 22 distinct research and development projects, the board of directors recognise that the Company's core strategic imperative to develop a diversified base of high-quality proprietary assets has been firmly established. The key imperative for Incannex now is the development of the Company's proprietary drug candidates over which proof of concept has been established.

Further to the appointments of Dr Anastassov and Mr Changoer, a recruitment process is currently taking place for several full-time candidates with medical development and pharmaceutical commercialisation experience. Candidates from the United States are being sought.

Dr Agarwal's resignation will also alleviate potential future conflict of interest issues pertaining to work undertaken by Cannvalate Pty Ltd, Dr Agarwal's medicinal cannabis advisory firm.

Dr Agarwal explained, "It is with some sadness that I move on from IHL and I wish the company success in its future drug development plans."

Incannex's Managing Director and CEO, Mr Joel Latham said: "The Board of Incannex wishes to thank Dr Agarwal for his work on behalf of the Company and wishes him well for his future endeavours."

**This announcement has been approved for release to ASX by the Incannex board of directors.**

**END**

### **About Incannex Healthcare Limited**

Incannex is a clinical stage pharmaceutical development company that is developing unique medicinal cannabis pharmaceutical products and psychedelic medicine therapies for the treatment of anxiety disorders, obstructive sleep apnoea (OSA), traumatic brain injury (TBI)/concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis and inflammatory bowel disease. U.S. FDA approval and registration, subject to ongoing clinical success, is being pursued for each drug and therapy under development. Each indication represents major global markets and currently have no, or limited, existing registered pharmacotherapy (drug) treatments available to the public.

Incannex has a strong patent filing strategy in place as it develops its products and therapies in conjunction with its medical and scientific advisory board and partners. Incannex is listed on the Australian Stock Exchange (ASX) with stock code "IHL" and also has American Depository Shares listed on NASDAQ under code "IXHL".

**Website: [www.incannex.com.au](http://www.incannex.com.au)**  
**Investors: [investors@incannex.com.au](mailto:investors@incannex.com.au)**

Incannex Healthcare Limited (ABN: 93 096 635 246)  
Level 23, Rialto South Tower, 525 Collins Street, Melbourne VIC 3000  
P: +61 409 840 786

### **Forward-looking statements**

This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements are made as of the date they were first issued and were based on current expectations and estimates, as well as the beliefs and assumptions of management. The forward-looking statements included in this press release represent Incannex's views as of the date of this press release. Incannex anticipates that subsequent events and developments may cause its views to change. Incannex undertakes no intention or obligation to update or revise any forward-looking statements, whether as of a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing Incannex's views as of any date after the date of this press release.

### **Contact Information**

#### **Incannex Healthcare Limited**

Mr Joel Latham  
Managing Director and Chief Executive Officer  
+61 409 840 786  
joel@incannex.com.au

#### **US IR Contact**

Rx Communications Group  
Michael Miller  
+1-917-633-6086  
mmiller@rxir.com

Incannex Healthcare Limited (ABN: 93 096 635 246)  
Level 23, Rialto South Tower, 525 Collins Street, Melbourne VIC 3000  
P: +61 409 840 786



Date: June 27, 2022  
Public Announcement (NASDAQ: IXHL) (ASX: IHL)

**Incannex to Present at the H.C. Wainwright First Annual  
Mental Health Conference**

**Melbourne, Australia, June 27, 2022 – Incannex Healthcare Limited (NASDAQ: IXHL) (ASX: IHL)**, ('Incannex' or the 'Company') a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, today announced that Dr. Paul Liknaitzky, Head of Clinical Psychedelic Research at Monash University and Chief Principal Investigator for Incannex's psilocybin-assisted psychotherapy, will present an overview of progress achieved in Incannex's psychedelic medicine program at the H.C. Wainwright First Annual Mental Health Conference, taking place June 27, 2022. Joel Latham, Managing Director and Chief Executive Officer of Incannex, will host virtual meetings with institutional investors during the conference.

The on-demand presentation will be available for viewing beginning at 7:00 a.m. US ET on June 27, 2022. A webcast of the presentation will be available on Incannex's website at: <https://www.incannex.com.au/investors/> and will be archived for a period of 90 days following the event.

**This announcement has been approved for release to ASX by the Incannex board of directors.**

**END**

**About Incannex Healthcare Limited**

Incannex is a clinical stage pharmaceutical development company that is developing unique medicinal cannabis pharmaceutical products and psychedelic medicine therapies for the treatment of anxiety disorders, obstructive sleep apnoea (OSA), traumatic brain injury (TBI)/concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis and inflammatory bowel disease. U.S. FDA approval and registration, subject to ongoing clinical success, is being pursued for each drug and therapy under development. Each indication represents major global markets and currently have no, or limited, existing registered pharmacotherapy (drug) treatments available to the public.

Incannex has a strong patent filing strategy in place as it develops its products and therapies in conjunction with its medical and scientific advisory board and partners. Incannex is listed on the Australian Stock Exchange (ASX) with stock code "IHL" and also has American Depository Shares listed on NASDAQ under code "IXHL".

**Website: [www.incannex.com.au](http://www.incannex.com.au)**  
**Investors: [investors@incannex.com.au](mailto:investors@incannex.com.au)**

Incannex Healthcare Limited (ABN: 93 096 635 246)  
Level 39, Rialto South Tower, 525 Collins Street, Melbourne VIC 3000  
P: +61 409 840 786



### Forward-looking statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements are made as of the date they were first issued and were based on current expectations and estimates, as well as the beliefs and assumptions of management. The forward-looking statements included in this press release represent Incannex’s views as of the date of this press release. Incannex anticipates that subsequent events and developments may cause its views to change. Incannex undertakes no intention or obligation to update or revise any forward-looking statements, whether as of a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing Incannex’s views as of any date after the date of this press release.

### Contact Information

#### Incannex Healthcare Limited

Mr Joel Latham  
Managing Director and Chief Executive Officer  
+61 409 840 786  
joel@incannex.com.au

#### US IR Contact

Rx Communications Group  
Michael Miller  
+1-917-633-6086  
mmiller@rxir.com

Incannex Healthcare Limited (ABN: 93 096 635 246)  
Level 39, Rialto South Tower, 525 Collins Street, Melbourne VIC 3000  
P: +61 409 840 786